Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IACS-010759 in Relapsed or Refractory AML
NCT02882321Phase 1Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2016
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of IACS-010759 in acute myeloid leukemia (AML) (4 cohorts), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose up to 28 days. Started Sep 2016; status: terminated.
02
Drugs
IACS-010759
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02882321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02882321.